AOP Health Presents New Findings Regarding Consistent Hematologic Response of Patients With polycythaemia vera
AOP Health announced new results on ropeginterferon alfa-2b (BESREMi®) from its clinical study CONTINUATION-PV in patients with polycythaemia vera (PV), a rare blood cancer. Professor Heinz Gisslinger from the Medical University of Vienna, Austria1 reported the findings in an abstract accepted for presentation at the prestigious EHA (European Hematology Association) 2023 Annual Meeting.
Link to CONTINUATION-PV Abstract.
Reducing the risk of thrombotic events is an important goal in the treatment of PV
The abstract accepted for presentation at the EHA 2023 Annual Meeting focused on the proportion of time individual patients spent with peripheral blood cells counts meeting the targets recommended to minimize thrombotic complications. This longitudinal analysis - an emerging method to assess thrombotic risk in PV - takes fluctuations of response over long-term treatment into account, which are not detectable in conventional analyses evaluating only a few distinct time points.
Professor Heinz Gisslinger from Vienna, first author of the paper stated that: “Results from the CONTINUATION-PV study have deepened our understanding of the benefits of long-term treatment with ropeginterferon alfa-2b, one of the few new treatments to become available for patients with PV in previous decades. This analysis demonstrates previously unknown differences between hematologic responses to ropeginterferon alfa-2b and best available treatment, which impact individual thrombotic risk.”
1 From snapshot to continuum: cumulative time in response as an emerging proxy for thrombotic risk in polycythaemia vera. Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, and Jean-Jacques Kiladjian for the PROUD-PV Study Group, European Haematology Association EHA, 28th Annual Meeting June 2023
About Polycythaemia Vera
Polycythaemia Vera (PV) is a rare cancer of the blood-building stem cells in the bone marrow resulting in a chronic increase of red blood cells, white blood cells and platelets. This condition increases the risk for circulatory disorders such as thrombosis and embolism, its symptoms lead to a reduced quality of life and on the long run may progress to myelofibrosis or transform to leukemia. While the molecular mechanism underlying PV is still subject of intense research, current results point to blood-building stem cells in the bone marrow with a set of acquired mutations, the most important being a mutant form of JAK2 that make up the malignant clone.
Important PV treatment goals are to achieve healthy blood counts (hematocrit below 45%), improve quality of life and to slow or delay the progression of disease.
About AOP Health
The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as also the healthcare professionals treating them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005430/en/
Contact information
Further inquiry
DI Isolde Fally
AOP Orphan Pharmaceuticals GmbH
Member of the AOP Health Group
Isolde.Fally@aop-health.com
+43-676-500 4048
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PPG opens Color Creation Lab with Chery Automobile in China1.6.2023 16:01:00 EEST | Press release
PPG (NYSE:PPG) today announced the opening of a Color Creation Lab in collaboration with automaker Chery Automobile Co., Ltd. At the facility, located in Wuhu, China, PPG color stylists and Chery designers will create new colors tailored to specific vehicle designs, from initial color recommendations to final materials for application in Chery’s manufacturing plants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005119/en/ Representatives from PPG and Chery Automobile celebrate the opening of a Color Creation Lab in Wuhu, China. (Photo: PPG) “As the leading single-source coatings supplier for automotive manufacturing, PPG is excited to partner with Chery, a company that prioritizes technological innovation and sustainable production,” said Thomas Li, PPG vice president Asia Pacific, Automotive Coatings. “We will leverage our global color leadership to predict future trends, while advancing paint technology for the nex
HEINZ® Unveils First Global Creative Brand Platform in Over 150 Years1.6.2023 16:00:00 EEST | Press release
Today, HEINZ announces “It Has to be HEINZ,” a new global platform marking the first time in its 150-year history where the brand is unified under one creative strategy. The campaign pays homage to the brand by celebrating the irrational love people have for HEINZ – from real fans’ personal love affairs with the brand, to the love and care its products are made with. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005186/en/ HEINZ announces its first new global platform in its 150-year history “It Has to be HEINZ,” inspired by real-life stories of fans’ undeniable love of HEINZ (Graphic: Business Wire) Anchored by Kraft HEINZ’s largest media investment to date, the global creative platform demonstrates the unmatched love generations of people all over the world have for HEINZ – from Ketchup to Beanz and everything in-between(z). The fan stories featured in the creative – such as HEINZ tattoos, carrying condiment packets
PPG opens $30-million battery pack application center in China1.6.2023 16:00:00 EEST | Press release
PPG (NYSE: PPG) today announced that it has inaugurated a battery pack application center (BPAC) in Tianjin, China. The $30-million facility features a full range of capabilities to test the application of PPG coatings technologies, materials and systems for electric vehicle (EV) battery packs, allowing customers to accelerate the development of new EV technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005106/en/ PPG has inaugurated a $30-million facility in Tianjin, China to test coatings technologies, materials and systems for electric vehicle battery packs. (Photo: Business Wire) “The new application center is an important milestone in our effort to support our customers in China in the EV battery market,” said Vincent Robin, PPG global vice president, Automotive Coatings. “The new facility will be an important way for customers to validate our customizable coatings solutions that help them reduce applicat
AlertEnterprise Appoints Greg Tomb to Board of Directors1.6.2023 16:00:00 EEST | Press release
AlertEnterprise, the only provider of AI-powered solutions for securing and automating total workforce management, is pleased to announce the appointment of Greg Tomb, a seasoned technology executive, to its Board of Directors. Tomb brings a wealth of experience in leading market-leading software and cloud organizations, including his tenure at SAP, President of SAP SuccessFactors, executive roles at Google Cloud and Zoom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005338/en/ Greg Tomb, former SAP® SuccessFactors® President and Google Cloud and Zoom executive joins AlertEnterprise's board of directors. (Photo: Business Wire) "We are delighted to welcome Greg Tomb to our esteemed Board of Directors. His extensive experience in driving innovation and growth in the HR, Security, and Enterprise Software market will be invaluable as we continue to deliver solutions that produce incredible workforce experiences, boosts p
Digi International Introduces Bold New Features to SkyCloud for Enhanced Industrial Monitoring and Control Solutions1.6.2023 16:00:00 EEST | Press release
Digi International, (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) connectivity products and services, today announced the release of the latest version of Digi SkyCloud, a state-of-the-art solution for monitoring, analyzing and controlling field data. The 23.5 update of SkyCloud introduces a range of new features, giving users effortless systems integrations with remote monitoring and control solutions — delivering flexibility and optimal efficiency, making it ideal for industrial, agricultural and environmental industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005484/en/ Digi International Introduces Bold New Features to SkyCloud for Enhanced Industrial Monitoring and Control Solutions (Graphic: Business Wire) Company administrators can now better manage their deployment and user base. At the forefront of this release are the introduction of REST APIs and the ability to d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom